Migraine Nasal Spray Market Attracts Innovation Amid Booming Neurology Drug Space with 6.5% CAGR (2024-2031) | Top Companies 2025 - Pfizer Inc., Impel Pharmaceuticals Inc., Upsher-Smith Laboratories, LLC.

"Global Migraine Nasal Spray Market reached US$ 520 million in 2024 and is expected to reach US$ 860 million by 2031, growing at a CAGR of 6.5% during the forecast period 2024-2031." As per DataM intelligence research report

Market growth opportunities(2025-2031):

Migraine Nasal Spray market is gaining momentum due to increasing migraine prevalence and growing preference for fast-acting, non-oral treatments. From 2025 to 2031, growth is driven by innovations like CGRP antagonist sprays such as zavegepant and advanced DHE-based formulations. Intranasal delivery systems offering rapid relief and improved patient compliance are becoming more popular. North America leads in market share, while Asia-Pacific shows rising adoption due to expanding healthcare access and awareness. Key challenges include high treatment costs, limited availability of advanced sprays, and occasional nasal side effects. The market remains promising with ongoing research and product enhancements.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/migraine-nasal-spray-market?sp

Migraine Nasal Spray Market: Recent Industry Developments

✅May 2025: The FDA approved Atzumi (previously STS101), the first dihydroergotamine (DHE) nasal powder for acute migraine in adults, utilizing SMART (Simple MucoAdhesive Release Technology)-a proprietary dry-powder delivery system

✅FDA approval granted on May 2025 for AtzumiTM (STS101), the first FDA-approved DHE nasal powder for acute migraine with or without aura in adults.

Migraine Nasal Spray Market: Technological Advancements

In March 2023, the FDA approved Pfizer's zavegepant nasal spray (Zavzpret)-the first CGRP receptor antagonist delivered via the nasal route-offering acute migraine relief in as little as 15 minutes for adults with or without aura.

Zavzpret's pivotal Phase III trials showed statistically significant results: approximately 24% of treated patients achieved pain freedom at two hours compared to 15% on placebo, with relief lasting up to 48 hours post-dose.

The Atzumi DHE spray demonstrated rapid efficacy in trials, with pain freedom reaching 37% at two hours and most bothersome symptom relief in up to 54% of treated attacks, sustaining benefit through 24 hours.

Trudhesa, a metered-dose DHE nasal spray employing POD technology, delivers medication into the upper nasal cavity's highly vascular area, enabling consistent absorption and relief onset as early as 15 minutes.

Strategic Players Driving the Migraine Nasal Spray Market Forward:

Pfizer Inc., Impel Pharmaceuticals Inc., Upsher-Smith Laboratories, LLC., Lannett Company, GlaxoSmithKline plc, SteriMax Inc., Assertio Therapeutics, Inc., Cipla Inc., AstraZeneca Plc. and Dr. Reddy's Laboratories Ltd. among others.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/migraine-nasal-spray-market?sp

Research Methodology:

The global Migraine Nasal Spray Market research report employs a comprehensive dual-source approach, integrating both primary and secondary data collection methods to ensure robust market analysis. Our research framework systematically evaluates multiple industry-influencing variables, including regulatory frameworks and government policies, prevailing market conditions, competitive intensity levels, historical performance data, current market positioning, technological innovations and disruptions, emerging industry developments, cross-sector business impacts, market volatility patterns, growth prospects, potential market barriers, and strategic challenges facing industry participants.

Segment Covered in the Migraine Nasal Spray Market:

✒By Chemical Type: Triptan Nasal Sprays, Dihydroergotamine Nasal Sprays, Nasal, Others

✒By Dosage: 5 mg, 10 mg, 20 mg, Others

✒By Application: Complicated Migraine, Common Migraine, Chronic Migraine, Ocular Migraine, Others

✒By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional Analysis for Migraine Nasal Spray Market:

The Migraine Nasal Spray market is expanding due to the rising incidence of migraines and demand for fast-acting, non-oral treatment options. North America, especially the U.S., leads with high awareness, early adoption of novel therapies, and robust pharmaceutical innovation. Europe, including Germany, the U.K., and France, shows steady growth supported by increasing diagnoses and access to advanced migraine care. Asia-Pacific, particularly Japan, India, and China, is witnessing rapid growth driven by urban lifestyles and improved healthcare access. South America is gradually adopting migraine sprays, mainly in urban pharmacy chains and private care settings. The Middle East & Africa show emerging demand, supported by increasing awareness and growing access to specialty medicines.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=migraine-nasal-spray-market?sp

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.